BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
最近の投稿
- 1
2024 Manual for Light Extravagance Room Feel: What's Moving - 2The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- 3Warming winters lead to more nitrate pollution in the drinking water near farms
- 4UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
- 5‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support
- Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- Vote In favor of Your Favored Distributed computing Administration
- A definitive Cruiser Standoff: Decision in favor of Your #1 Ride
- US measles cases surpass 2,000, highest in 30 years: CDC
- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- UAE recalls some Nestle infant formula products, Qatar warns consumers
- King Charles III says he is reducing cancer treatment schedule in 2026
